CRSP icon

CRISPR Therapeutics
CRSP

Upgrade to unlock
Buy
Hold
Sell

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$71
23% upside
High target

5 analyst ratings

positive
1  neutral
20%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Chardan Capital
Chardan Capital
Geulah Livshits
40% 1-yr CRSP win rate
17 Feb ‘26 2 months ago
TD Cowen
TD Cowen
Tyler Van Buren
13 Feb ‘26 2 months ago
Evercore ISI Group
Evercore ISI Group
Liisa Bayko
0% 1-yr CRSP win rate
13 Feb ‘26 2 months ago
Needham
Needham
Gil Blum
67% 1-yr CRSP win rate
13 Feb ‘26 2 months ago
Citizens
Citizens
Silvan Turkcan
0% 1-yr CRSP win rate
30 Jan ‘26 2 months ago